Your session is about to expire
← Back to Search
Guselkumab for Plaque Psoriasis (SPECTREM Trial)
SPECTREM Trial Summary
This trial will compare a possible psoriasis treatment to an inactive drug to see if it is effective.
SPECTREM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSPECTREM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SPECTREM Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the United States Food and Drug Administration (FDA) given its endorsement to Guselkumab for Group 1?
"Guselkumab's safety is well-documented due to its Phase 3 status, thus earning an assessment of 3 on the 1-3 scale."
How many participants have enrolled in this experiment?
"Correct. Clinicaltrials.gov confirms that this medical study, initially posted on August 24th 2023 is currently recruiting patients from four clinical centres with a goal of 300 participants total."
Is there a call for participants in this experiment presently?
"Affirmative. According to information present on clinicaltrials.gov, this medical experiment is actively seeking out participants with an initial post date of August 24th 2023 and an updated edit made September 9th 2023. The study aims to enlist 300 patients from 4 distinct sites."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger